Current and future treatments for relapsing-remitting multiple sclerosis.

Abstract

The last decades of the twentieth century ushered in the first treatments proven to modify the disease course of multiple sclerosis (MS). These breakthroughs in MS therapy stimulated an increase in the search for drugs with improved efficacy and greater ease of administration. This review summarizes the latest developments in the search for improved disease-modifying therapies and defines the efficacies and potential risks of such compounds. As with all new drugs, accurate assessments of risk:benefit ratios will be essential for the successful use of any agent targeting MS.